Drug intelligence / Profile preview

cyclophosphamide + imiquimod

Development stage: Preclinical
Lead developer: Takeda
Modality: Small Molecules
Administration: Topical, Oral, Intravenous

Overview

A combination therapy consisting of cyclophosphamide and imiquimod. Cyclophosphamide is an alkylating agent with immunomodulatory properties, while imiquimod is a toll-like receptor 7 (TLR7) agonist that stimulates immune responses. This combination has shown synergistic effects with radiation therapy in preclinical models of skin-involving breast cancer, demonstrating enhanced tumor inhibition and reduced recurrence rates compared to individual treatments.

Targets

TLR7 (Toll-like receptor 7)

Beyond the preview

Go deeper on cyclophosphamide + imiquimod.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + imiquimod.

Explore the full profile